Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Adeona Executes Agreement to Initiate Phase IIb Clinical Trial of Proprietary Zinc-Based Therapy in Lou Gehrig’s Disease (ALS)

June 23, 2011 By Bio-Medicine.Org

ANN ARBOR, Mich., June 23, 2011 /PRNewswire/ — Adeona
Pharmaceuticals, Inc. (NYSE Amex:
AEN
), a developer of innovative medicines for serious central
nervous system diseases, announced today that it has expanded its
pipeline of proprietary zinc-based therapies to include a planned
Phase IIb clinical trial of patients suffering from amyotrophic
lateral sclerosis (ALS), also known as Lou Gehrig’s Disease.
Preparations are underway to evaluate the safety and efficacy of
the Company’s proprietary drug candidates, AEN-100, a
gastroretentive, sustained-release zinc-based tablet, and AEN-200,
a copper tablet, in a multi-center, double-blind,
placebo-controlled clinical trial in ALS patients intended to be
conducted under an Investigational New Drug (IND) application.
Adeona will provide the study medications and fund the clinical
trial, which will be conducted by the neurology team at the PNA
Center for Neurological Research in collaboration with The
Institute for EthnoMedicine.

Planned Phase IIb Clinical Trial in ALS Patients Evaluating
Adeona’s Zinc-Based Therapy

Preparation of the planned Phase IIb clinical protocol is
currently ongoing for submission to the Food & Drug
Administration (FDA) as an addition to a current IND application.
Efforts are also underway for the manufacturing of clinical trial
medications and protocol review by an Institutional Review Board.
The multi-center trial is intended to take place at up to six major
ALS centers in the United States. It is anticipated that the trial
will enroll 60 ALS patients, who will continue on RILUTEK®
(riluzole) as the standard of care treatment. The patients will be
randomized into treatment and matching placebo groups and will
receive clinical trial medications for 12 months with periodic
monitoring. The treatment group will receive Adeona’s proprietary
drug candidates – AEN-100, a zinc-based tab

‘/>”/>

SOURCE

Related Articles Read More >

DeepWell Digital Therapeutics Mike Wilson Ryan Douglas
How DeepWell is developing video games as tools for treating medical conditions
A woman with a small, handheld device in her lap with tubes that look like earphones plugged into her ears.
Ear-puffing device for migraine treatment wins FDA breakthrough designation
Abbott
Abbott launches upgraded digital health app for neurostimulation
Catheter delivery could enable better brain implants: Synchron’s neuroscience chief explains how

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech